drugset / Trial / NCT00199433
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) as monotherapy in patients with Parkinson's disease.
Timeline
- Start
- 2005-05
- Primary completion
- 2006-07
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Istradefylline | Small molecule | 40 mg | — |